| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2023: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2022: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2021: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
|
|---|
| Outline of Final Research Achievements |
FOXP3+ regulatory T (Treg) cell acquire brain tissue-specific characteristics during the chronic stroke phase and contribute to neurological symptom recovery. Tregs in the periphery change their phenotype during the chronic stroke phase and can reduce inflammation and infarct volume during the recurrent stroke. Tregs increased in the brain during the acute phase of recurrence, and T cell receptor repertoire analysis revealed that Tregs recognizing identical antigens during the initial stroke also infiltrated the recurrent side of the subsequent stroke. The Treg increase depends on CCR4/CCL17 axis during stroke recurrence. These results suggest that Tregs infiltrate rapidly the brain with antigens and chemokines during stroke recurrence, contributing to immunosuppression and tissue repair. Unexpectedly, oxytocin increases in the brain after a stroke, plays an essential role in tissue repair and inflammation inhibition, and contributes to ischemic resistance during recurrence.
|
